1. Continued signs of resilience in the European drug market: Highlights from the EMCDDA's 2016 European drug report. (1st November 2016) Authors: Mounteney, Jane; Griffiths, Paul; Cunningham, Andrew; Evans-Brown, Michael; Ferri, Marica; Hedrich, Dagmar; Noor, Andre Journal: Drugs Issue: Volume 23:Number 6(2016:Dec.) Page Start: 492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fentanils: a serious threat to public health. (18th January 2019) Authors: Mounteney, Jane; Griffiths, Paul; Sedefov, Roumen; Evans‐Brown, Michael Journal: Addiction Issue: Volume 114:Number 5(2019) Page Start: 783 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Increasing complexity in European drug use: Highlights from the EMCDDA's 2014 European drug report. (December 2014) Authors: Mounteney, Jane; Griffiths, Paul Journal: Drugs Issue: Volume 21:Number 6(2014:Dec.) Page Start: 482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Is Europe facing an opioid epidemic: What does European monitoring data tell us?. (2nd February 2021) Authors: Seyler, Thomas; Giraudon, Isabelle; Noor, André; Mounteney, Jane; Griffiths, Paul Journal: European journal of pain Issue: Volume 25:Number 5(2021) Page Start: 1072 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Looking to the future—more concern than optimism that cryptomarkets will reduce drug‐related harms. (19th November 2017) Authors: Mounteney, Jane; Cunningham, Andrew; Groshkova, Teodora; Sedefov, Roumen; Griffiths, Paul Journal: Addiction Issue: Volume 113:Number 5(2018) Page Start: 799 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Regulatory approaches to cannabidiol in the European Union: are market developments sowing the seeds of confusion?. (11th August 2021) Authors: Hughes, Brendan; Vandam, Liesbeth; Mounteney, Jane; Griffiths, Paul Journal: Addiction Issue: Volume 117:Number 1(2022) Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. (30th September 2015) Authors: Mounteney, Jane; Griffiths, Paul; Sedefov, Roumen; Noor, Andre; Vicente, Julián; Simon, Roland Journal: Addiction Issue: Volume 111:Number 1(2016) Page Start: 34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The European drug landscape in 2013 – Highlights from the EMCDDA's European drug report. (2013) Authors: Mounteney, Jane; Zobel, Frank; Griffiths, Paul Journal: Drugs Issue: Volume 20:Number 5(2013:Oct.) Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The same fundamental drivers but differently expressed: what can we learn from comparing the recent experiences with synthetic opioids in the US and Europe?. (15th January 2021) Authors: Griffiths, Paul; Mounteney, Jane; Sedefov, Roumen Journal: Addiction Issue: Volume 116:Number 6(2021) Page Start: 1314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Trends in MDMA‐related mortality across four countries. (15th April 2021) Authors: Roxburgh, Amanda; Sam, Bulent; Kriikku, Pirkko; Mounteney, Jane; Castanera, Antonio; Dias, Mario; Giraudon, Isabelle Journal: Addiction Issue: Volume 116:Number 11(2021) Page Start: 3094 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗